Form 8-K - Current report:
SEC Accession No. 0001213900-24-058821
Filing Date
2024-07-03
Accepted
2024-07-03 09:40:50
Documents
15
Period of Report
2024-07-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0207151-8k_emmaus.htm   iXBRL 8-K 27194
2 JULY 3, 2024 PRESS RELEASE ea020715101ex99-1_emmaus.htm EX-99.1 41100
3 GRAPHIC ex99-1_001.jpg GRAPHIC 3635
  Complete submission text file 0001213900-24-058821.txt   249783

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE emma-20240703.xsd EX-101.SCH 3030
5 XBRL LABEL FILE emma-20240703_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE emma-20240703_pre.xml EX-101.PRE 22369
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0207151-8k_emmaus_htm.xml XML 3359
Mailing Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503
Business Address 21250 HAWTHORNE BOULEVARD, SUITE 800 TORRANCE CA 90503 310-214-0065
Emmaus Life Sciences, Inc. (Filer) CIK: 0000822370 (see all company filings)

EIN.: 870419387 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35527 | Film No.: 241098444
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)